Breast Cancer, Neoplasm Metastasis
Conditions
Brief summary
Tolerance and efficacy of administration of capecitabine 5 out of 7 days associated with weekly paclitaxel compared to the recommended treatment plan of weekly paclitaxel - capecitabine, in patients with metastatic breast cancer.
Detailed description
The purpose of this study is to know if we can optimize in term of tolerance even of efficacy the plan of administration of weekly paclitaxel associated with capecitabine.
Interventions
DRUGPaclitaxel
DRUGCapecitabine
Sponsors
ARCAGY/ GINECO GROUP
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Femal patient aged \> 18 years * Histologically proven breast adenocarcinoma * HER2 negative receptors * previously received first or second line chemotherapy for metastatic disease * previously treated with anthracycline and/or docetaxel in adjuvant and/or as first or second line therapy * presence of one or several evaluable metastatic lesion(s) * presence of at least one target lesion not previously irradiated * previously treated with hormonotherapy in adjuvant or in metastatic line (treatment will be ceased upon patient registration in the study) * ECOG Performance status \< 2 * adequate biological values * patient who has clearly given her consent by signing on informed consent form prior to participation
Exclusion criteria
* patient previously treated with paclitaxel or capecitabine for metastatic breast cancer * patient with only local metastatic disease (with the exception of axillary lymph nodes) * active symptomatic brain metastasis * patient with an history of significant cardiovascular impairment (congestive heart failure\> NYHA grade II, unstable angina or myocardial infraction within the past six months or serious cardiac arrhythmia) * peripheric neuropathy grade ≥ 2 * history of another malignancy within past 5 years that could confound diagnosis or staging of breast cancer (with the exception of in situ cacinoma of the cervix or adequately treated basel cell carcinoma of the skin) * patient with any medical or psychiatric condition that, in the opinion of the Principal Investigator, would preclude her from participating in this study * patient with a known allergy to one or several of the study compounds * patients who may not be regularly available due to geographical, social or family reasons * history of renal, hepatic or metabolic pathology that could preclude with metabolism or elimination of the study product * deficiencies of the upper intestinal tract, malabsorption syndrome * patient who is pregnant, breast-feeding or using inadequate contraception
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| tolerance of the patients in the both groups. | — |
Secondary
| Measure | Time frame |
|---|---|
| - Response rates and duration of response. | — |
| - Haematological and non-haematological toxicities. | — |
| - Progression free survival. | — |
| - Overall survival. | — |
Countries
France
Outcome results
None listed